WordNet

resembling a capsule; "the capsular ligament is a sac surrounding the articular cavity of a freely movable joint and attached to the bones"
of or relating to a capsule
immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
any of a class of carbohydrates whose molecules contain chains of monosaccharide molecules (同)polyose
of or derived from or caused by bacteria of the genus pneumococcus

PrepTutorEJDIC

カプセルの,カプセル状の,カプセルに入った
牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児における肺炎球菌（肺炎レンサ球菌）多糖類ワクチン pneumococcal streptococcus pneumoniae polysaccharide vaccines in children
2. 成人における肺炎球菌ワクチン pneumococcal vaccination in adults
3. 小児における肺炎球菌（肺炎レンサ球菌）結合型ワクチン pneumococcal streptococcus pneumoniae conjugate vaccines in children
4. 予防接種に対する免疫応答の評価 assessing the immunologic response to vaccination
5. 妊娠中の予防接種 immunizations during pregnancy

English Journal

Delivery of Polysaccharides Using Polymer Particles: Implications on Size-Dependent Immunogenicity, Opsonophagocytosis, and Protective Immunity.

Anish C, Khan N, Upadhyay AK, Sehgal D, Panda AK.Author information Product Development Cell, ‡Molecular Immunology Laboratory, National Institute of Immunology , Aruna Asaf Ali Marg, New Delhi 110067, India.AbstractBacterial capsular polysaccharides are components of many modern vaccines, but they are weakly immunogenic. Herein, we describe the delivery of pneumococcal capsular polysaccharide serotype-1 (PCP-1) in polylactide polymeric particles to enhance its immunogenicity. Immunization with PCP-1-entrapped particles elicited long-term memory antibody responses from a single intramuscular injection. PCP-1-entrapped nanoparticles (NPs) elicited significantly higher anti-PCP-1 IgG responses than that observed with soluble and microparticles (MPs) formulations. Delivering PCP-1 and pneumococcal proteins in same particles did not improve the IgG response. The sera of animals immunized with PCP-1-entrapped particles promoted efficient opsonophagocytosis of pneumococci by macrophages. Single-dose immunization with PCP-1-entrapped particles conferred a long-term serotype-specific protection against lethal pneumococcal challenge. The higher immunogenicity of PCP-1 nanoparticles showed correlation with enhanced uptake by antigen-presenting cells. The results highlight the potential of polymeric nanoparticles as an efficient means of presenting polysaccharide antigens to the immune system.
Molecular pharmaceutics.Mol Pharm.2014 Jan 29. [Epub ahead of print]
Bacterial capsular polysaccharides are components of many modern vaccines, but they are weakly immunogenic. Herein, we describe the delivery of pneumococcal capsular polysaccharide serotype-1 (PCP-1) in polylactide polymeric particles to enhance its immunogenicity. Immunization with PCP-1-entrapped
PMID 24446810

Structure elucidation of capsular polysaccharides from Streptococcus pneumoniae serotype 33C, 33D, and revised structure of serotype 33B.

Lin FL1, Vinogradov E2, Deng C3, Zeller S3, Phelan L3, Green BA3, Jansen KU3, Pavliak V3.Author information 1Pfizer Vaccine Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. Electronic address: fiona.lin@pfizer.com.2Institute for Biological Sciences, National Research Council, 100 Sussex Dr., Ottawa, ON K1A 0R6, Canada.3Pfizer Vaccine Research, 401 N. Middletown Road, Pearl River, NY 10965, USA.AbstractWe report herein the previously unknown structures of the pneumococcal capsular polysaccharides serotype 33C and 33D, and a revised structure of serotype 33B. The syntenic pair 33B/33D has nearly identical polysaccharide repeat units with the exception of one sugar residue (→2-α-Glcp in 33B and →2-α-Galp in 33D). Serotype 33C is structurally more similar to 33B/33D than 33A/33F, in that it also possesses a backbone ribitol-phosphate group and a →3-β-GalpNAc residue, both of which are absent in the repeat units of 33A/33F. Serotype 33C is notably different from all other serogroup 33 polysaccharides, as there is no →3-β-Glcp residue and the location of the O-acetylation of the →5-β-Galf residue (O-6) differs from the other serogroup 33 polysaccharides (O-2). This completes the structural assignments of polysaccharides within serogroup 33 and provides a framework for understanding the recognition of epitopes by serogroup 33 typing sera based on observed cross-reactivities reported in the literature.
Carbohydrate research.Carbohydr Res.2014 Jan 13;383:97-104. doi: 10.1016/j.carres.2013.11.006. Epub 2013 Nov 19.
We report herein the previously unknown structures of the pneumococcal capsular polysaccharides serotype 33C and 33D, and a revised structure of serotype 33B. The syntenic pair 33B/33D has nearly identical polysaccharide repeat units with the exception of one sugar residue (→2-α-Glcp in 33B and �
PMID 24334220

Role of vaccination in preventing pneumococcal disease in adults.

Aliberti S, Mantero M, Mirsaeidi M, Blasi F.Author information Department of Health Science, University of Milan Bicocca, Clinica Pneumologica, AO San Gerardo, Via Pergolesi 33, Monza, Italy.AbstractPneumococcal infections, including pneumonia and invasive disease (IPD), are major sources of morbidity and mortality worldwide. Prevention of first acquisition of S. pneumoniae with the use of vaccines represents an effective method to reduce the burden of the disease in both children and adults. Two vaccines are currently available in adults: a pneumococcal polysaccharide vaccine (PPV23) that includes 23 purified capsular polysaccharide antigens and a pneumococcal protein-conjugate vaccine (PCV13) that includes capsular polysaccharide antigens covalently linked to a non-toxic protein. The PPV23 induces a humoral immune response and since it has been licensed, it has been the subject of debates and controversies. Numerous studies and meta-analyses have shown that PPV23 protects against IPD, although there are conflicting data regarding its efficacy for the prevention of pneumonia. Vaccination with PCV13 stimulates good antibody responses as well as mucosal antibody and suppresses colonization. A conjugate vaccine can be expected to have benefits over a polysaccharide vaccine, due to the characteristics of a T-cell dependent response in terms of affinity, maturation of antibodies with repeated exposure, induction of immunological memory and long lasting immunity. The PCV13 has demonstrated all these characteristics in children and fundamental differences in adults are not expected. The efficacy in adults is currently being investigated and results will be available soon. This article is protected by copyright. All rights reserved.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.Clin Microbiol Infect.2014 Jan 10. doi: 10.1111/1469-0691.12518. [Epub ahead of print]
Pneumococcal infections, including pneumonia and invasive disease (IPD), are major sources of morbidity and mortality worldwide. Prevention of first acquisition of S. pneumoniae with the use of vaccines represents an effective method to reduce the burden of the disease in both children and adults. T
PMID 24410778

Japanese Journal

肺炎球菌予防戦略の展開-結合型ワクチンの中耳炎予防効果は?

中野貴司
小児耳鼻咽喉科 32(3), 297-304, 2011-12-01
NAID 10030290524

慢性呼吸器疾患患者における23価肺炎球菌ワクチン接種前後の血清型特異抗体濃度の検討

斉藤若奈,永井英明,鈴木純子,益田公彦,田村厚久,長山直弘,赤川志のぶ,川辺芳子,町田和子,倉島篤行,四元秀毅,斉藤剛,新井智,岡部信彦
日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society 43(5), 277-282, 2005-05-10
NAID 10016604388

肺炎球菌ワクチンによる脾摘後重症感染症の予防に関する研究

冲永功太,岡田久恵,和田信昭,佐藤久聡,中野和美
日本小児外科学会雑誌 20(5), 931-937, 1984-08-20
… Effect of pneumococcal capsular polysaccharide vaccine on pneumococcal bacteremia was studied in three-week-old Sprague-Dawley rats. …
NAID 110002096531